The potency of acyclovir can be markedly different in different cell types
- PMID: 11521752
- DOI: 10.1016/s0024-3205(01)01213-9
The potency of acyclovir can be markedly different in different cell types
Abstract
Acyclovir is an acyclic guanine analog with a considerable activity against herpes simplex viruses. We studied the antiherpetic activity of acyclovir in macrophages and fibroblast cell lines. Utilising a plaque reduction assay we found that acyclovir potently inhibited the HSV-1 replication in macrophages (EC50) = 0.0025 microM) compared to Vero (EC50 = 8.5 microM) and MRC-5 (EC50 = 3.3 microM) cells. The cytotoxicity of acyclovir was not detected at concentrations < or = 20 microM, thus the selective index in macrophages was >8000. This marked difference in antiherpetic activity between macrophages and fibroblasts was not observed with Foscarnet and PMEA. We suggest that this potent antiviral effect of acyclovir is mainly due to a proficient phosphorylation of the drug and/or a favourable dGTP/acyclovir triphosphate ratio in macrophage cells.
Similar articles
-
Herpes simplex virus-1 entrapped in Candida albicans biofilm displays decreased sensitivity to antivirals and UVA1 laser treatment.Ann Clin Microbiol Antimicrob. 2017 Nov 14;16(1):72. doi: 10.1186/s12941-017-0246-5. Ann Clin Microbiol Antimicrob. 2017. PMID: 29137671 Free PMC article.
-
A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity.Int J Antimicrob Agents. 2009 Aug;34(2):177-80. doi: 10.1016/j.ijantimicag.2009.02.025. Epub 2009 Apr 24. Int J Antimicrob Agents. 2009. PMID: 19394201
-
Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir.AIDS Res Hum Retroviruses. 1998 Mar 20;14(5):435-44. doi: 10.1089/aid.1998.14.435. AIDS Res Hum Retroviruses. 1998. PMID: 9546803
-
Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR.Antiviral Res. 2006 Mar;69(3):152-7. doi: 10.1016/j.antiviral.2005.11.004. Epub 2005 Dec 19. Antiviral Res. 2006. PMID: 16388859
-
Potent inhibition of human immunodeficiency virus and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines.Mol Pharmacol. 1996 Aug;50(2):359-66. Mol Pharmacol. 1996. PMID: 8700144
Cited by
-
A TRUSTED targeted mass spectrometry assay for pan-herpesvirus protein detection.Cell Rep. 2022 May 10;39(6):110810. doi: 10.1016/j.celrep.2022.110810. Cell Rep. 2022. PMID: 35545036 Free PMC article.
-
A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.PLoS Pathog. 2013;9(7):e1003456. doi: 10.1371/journal.ppat.1003456. Epub 2013 Jul 25. PLoS Pathog. 2013. PMID: 23935482 Free PMC article.
-
Tranylcypromine reduces herpes simplex virus 1 infection in mice.Antimicrob Agents Chemother. 2014 May;58(5):2807-15. doi: 10.1128/AAC.02617-13. Epub 2014 Mar 3. Antimicrob Agents Chemother. 2014. PMID: 24590478 Free PMC article.
-
Effect of the N-butanoyl glutathione (GSH) derivative and acyclovir on HSV-1 replication and Th1 cytokine expression in human macrophages.Med Microbiol Immunol. 2014 Aug;203(4):283-9. doi: 10.1007/s00430-014-0335-4. Epub 2014 Mar 29. Med Microbiol Immunol. 2014. PMID: 24682316
-
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.Lancet. 2012 Feb 18;379(9816):641-7. doi: 10.1016/S0140-6736(11)61750-9. Epub 2012 Jan 4. Lancet. 2012. PMID: 22225814 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources